Kodiak Sciences (KOD) Received its Third Buy in a Row

By Carrie Williams

After Chardan Capital and Morgan Stanley gave Kodiak Sciences (NASDAQ: KOD) a Buy rating last month, the company received another Buy, this time from Barclays. Analyst Gena Wang maintained a Buy rating on Kodiak Sciences yesterday and set a price target of $26.00. The company’s shares closed last Monday at $23.38, close to its 52-week high of $24.25.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 17.4% and a 49.4% success rate. Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Orchard Therapeutics, and Puma Biotechnology.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kodiak Sciences with a $33.00 average price target, which is a 51.4% upside from current levels. In a report issued on November 5, Morgan Stanley also maintained a Buy rating on the stock with a $33.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.25 and a one-year low of $5.65. Currently, Kodiak Sciences has an average volume of 272.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.